Full Text Journal Articles by
Author Kurt R Oettel

Advertisement

Find full text journal articles








American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Nathan A Pennell, Melissa Dillmon, Laura A Levit, E Allyn Moushey, Ajjai S Alva, Sibel Blau, Timothy L Cannon, Natalie R Dickson, Maximilian Diehn, Mithat Gonen, Maria Magdalena Gonzalez, Jack O Hensold, Leslie J Hinyard, Tari King, Stacie C Lindsey, Allison Magnuson, Jonathan Marron, Barbara L McAneny, Theresa M McDonnell, Kathryn Finch Mileham, Shelley Fuld Nasso, Grzegorz S Nowakowski, Kurt R Oettel, Manali I Patel, Debra A Patt, Jane Perlmutter, Todd A Pickard, Gladys Rodriguez, Abby R Rosenberg, Barry Russo, Connie Szczepanek, Cardinale B Smith, Piyush Srivastava, Eleonora Teplinsky, Ramya Thota, Tiffany A Traina, Robin Zon, Brian Bourbeau, Suanna S Bruinooge, Shelagh Foster, Stephen Grubbs, Karen Hagerty, Patricia Hurley, Deborah Kamin, Jonathan Phillips, Caroline Schenkel, Richard L Schilsky, Howard A Burris,

This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(2):155-169]

Cited: 9 times

View full text PDF listing >>



Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study.

Agnes Smaradottir, Angela L Smith, Andrew J Borgert, Kurt R Oettel,

<b>Background:</b> Physical activity (PA) during and after cancer treatment can help with symptom management and reduce the risk of cancer recurrence. However, it is unclear what constitutes an optimal exercise program. In addition, provider and patient barriers exist to the recommendation and adoption of exercise as part of a cancer ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2017, 15(5):588-594]

Cited: 12 times

View full text PDF listing >>



Advertisement

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Tien Hoang, Toby C Campbell, Chong Zhang, Kyungmann Kim, Jill M Kolesar, Kurt R Oettel, Jules H Blank, Emily G Robinson, Harish G Ahuja, Ron J Kirschling, Peter H Johnson, Michael S Huie, Mary E Wims, Martha M Larson, Hilary R Hernan, Anne M Traynor,

<h4>Introduction</h4>The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC) patients.<h4>Methods</h4>Eligibility criteria included recurrent/metastatic NSCLC, having received 2 prior systemic regimens, and performance status 0-2. Patients took vorinostat 400 mg PO ... Read more >>

Invest New Drugs (Investigational new drugs)
[2014, 32(1):195-199]

Cited: 20 times

View full text PDF listing >>



Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

Anne M Traynor, Tracey L Weigel, Kurt R Oettel, David T Yang, Chong Zhang, Kyungmann Kim, Ravi Salgia, Mari Iida, Toni M Brand, Tien Hoang, Toby C Campbell, Hilary R Hernan, Deric L Wheeler,

<h4>Introduction</h4>Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC).<h4>Methods</h4>Resected stages I and II NSCLC ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2013, 81(1):138-141]

Cited: 38 times

View full text PDF listing >>



Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.

Steven Attia, Anne M Traynor, Kyungmann Kim, Joseph J Merchant, Tien Hoang, Harish G Ahuja, Peter A Beatty, Richard M Hansen, Gregory A Masters, Kurt R Oettel, Gary R Shapiro, Martha M Larson, Marilyn L Larson, Joan H Schiller,

<h4>Introduction</h4>Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC.<h4>Methods</h4>Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2008, 3(9):1018-1025]

Cited: 0 times

View full text PDF listing >>



A morphealike skin condition caused by Borrelia burgdorferi in an immunocompromised patient.

Jeffrey S Sartin, Kurt R Oettel,

Mayo Clin Proc (Mayo Clinic proceedings)
[2006, 81(9):1259-60, 1263]

Cited: 1 time

View full text PDF listing >>



Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.

Tien Hoang, KyungMann Kim, Joseph Merchant, Anne M Traynor, James McGovern, Kurt R Oettel, Fredrico A Sanchez, Harish G Ahuja, Thomas A Hensing, Martha Larson, Joan H Schiller,

<h4>Background</h4>The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced non-small cell lung cancer.<h4>Methods</h4>Patients whose disease progressed more than 3 months from completion of first-line chemotherapy were eligible for this phase ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2006, 1(3):218-225]

Cited: 5 times

View full text PDF listing >>





Advertisement


Disclaimer

0.7849 s